(Image source from: news.sky.com)

Fortunately, we see a spark of light through the dark path of Coronavirus that has left the world.

On Wednesday, Johnson and Johnson via Janssen Pharmaceutical Companies has said to take its first in-human clinical trial of the investigational SARS-CoV-2 vaccine forward in the end of July.

In the beginning of September, the trial for the vaccine Ad26.COV2-S, recombinant was to take place.

After looking into every possibility of preclinical data and interacting with authorities, Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson and Johnson, said “Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.”

Further in a statement, he said, "Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities."

Study of this virus will take place in the US and Belgium. Safety, reactogenicity (response to vaccination), immunogenicity (immune response) of this vaccine in 1,045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older will be observed and studied further.

The company’s goal is to deliver a vaccine to the world and protect people suffering with this pandemic.

Right now, there are over 100 vaccines under various stages of trial. For a successful one to be made it will take between 12 to 18 months.

The company aims at starting Phase 3 of its clinical trial and it is in discussion with the National Institutes of Allergy and Infectious Diseases on this. Since there has been a pending outcome in the Phase 1 studies, they are awaiting approval of the regulators.

By Neha Makhija